Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
$NTRB reaches a new 52-week high of $9.00 and closes at $8.99, extending a powerful September advance as the company
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
The move represents another dramatic step in a September rally that has brought NTRB from a $4.72 September 3 opening price to today’s $8.99 close. The stock has therefore gained roughly 90% from that September 3 opening level, while the September 24 session alone added $1.64 per share.
For investors watching the company, however, the stock-price breakout is occurring at an especially interesting time.
Nutriband is simultaneously approaching a major warrant deadline, advancing intellectual-property and commercialization initiatives surrounding AVERSA™, and increasing its visibility within the Nasdaq life-sciences community.
A New 52-Week High Changes the Conversation
Today’s trading session was significant not simply because NTRB rose sharply, but because the stock pushed into a new 52-week high of $9.00.
NTRB opened at $7.35, traded as low as $7.35, and then climbed to $9.00 before finishing at $8.99.
That represents a remarkable intraday move of approximately 22.4% from the opening price and puts the stock firmly into new territory for the trailing 52-week period.
The progression throughout September is also notable:
- Sept. 3: closed at $5.63
- Sept. 11: closed at $6.96
- Sept. 17: closed at $7.65
- Sept. 18: closed at $8.13
- Sept. 23: closed at $7.35
- Sept. 24: $9.00 intraday / $8.99 close
The stock’s September momentum is therefore occurring against a backdrop of substantial volatility rather than a straight-line advance. That distinction is important for investors evaluating what happens next.
The Warrant Clock Is Now Ticking Loudly
One of the biggest near-term developments surrounding NTRB is the company’s publicly traded warrants, N A S D A Q: NTRBW.
And there has been an important update since our previous article.
On September 22, Nutriband officially confirmed that the outstanding publicly traded warrants will expire September 30, 2026 at 5:00 p.m. Eastern Time. The company specifically stated that it will not extend or reprice the warrants.
There are currently 910,904 warrants outstanding, each with a $6.43 exercise price. If every one of those warrants were exercised at $6.43, Nutriband would receive approximately $5.856 million in gross proceeds.
With NTRB closing today at $8.99, the common stock is approximately $2.56 above the $6.43 warrant exercise price.
That creates a particularly interesting situation heading into the final trading days before expiration.
Warrants that are not exercised by the deadline will expire and become void. The company has also confirmed that trading in NTRBW will cease at the close of trading on September 30.
For investors, the key numbers are now unmistakable:
910,904 — public warrants outstanding
$6.43 — exercise price
$5.856 million — potential gross proceeds if fully exercised
September 30, 2026 — expiration at 5:00 p.m. ET
AVERSA™ Remains the Bigger Story
While today’s stock move is attracting attention, the fundamental development story remains Nutriband’s AVERSA™ abuse-deterrent transdermal technology.
Nutriband is developing AVERSA™ Fentanyl as an abuse-deterrent fentanyl transdermal system designed to address risks associated with abuse, misuse, diversion and accidental exposure.
The company has described AVERSA™ as a platform that can be incorporated into transdermal patches containing drugs with abuse potential. Nutriband’s broader AVERSA development pipeline includes additional potential applications beyond fentanyl.
Importantly, the company has also reported AVERSA-related patent protection in 46 countries, adding an extensive intellectual-property component to the potential commercial opportunity.
USPTO Development Adds Another Piece
Earlier this month, Nutriband announced that it received a USPTO Notice of Publication for commercial brand-name trademarks associated with its lead abuse-deterrent fentanyl transdermal system.
The trademarks are subject to a 30-day opposition period, after which the company could potentially proceed toward a Notice of Allowance. Nutriband has said the proposed commercial brand name and product labeling are intended for submission to the FDA and international regulatory agencies as part of its development strategy.
The company has previously estimated potential peak annual U.S. sales for its abuse-deterrent fentanyl product in the range of $80 million to $200 million. That figure is a company projection, not current revenue or a guarantee of future sales.
Nasdaq Visibility Continues to Grow
Nutriband CEO Gareth Sheridan also participated in the inaugural N A S D A Q Life Sciences Advisory Board (LaB) Biotech Summit at Nasdaq MarketSite in New York on September 16.
The event brought together biotechnology executives, investors and industry participants and provided another opportunity for Nutriband management to present the company’s story within the broader life-sciences investment community.
A Particularly Interesting Moment for NTRB
Today’s new 52-week high arrives with several important developments converging simultaneously.
The stock has broken into new 52-week territory.
The September 30 warrant expiration is only days away.
The $6.43 warrant exercise price remains well below today’s $8.99 closing price.
Up to approximately $5.856 million in gross proceeds could result if all 910,904 public warrants are exercised.
AVERSA™ continues progressing toward its potential commercialization pathway.
The company’s intellectual-property and trademark position continues developing.
For prospective investors, that combination makes the next several trading sessions particularly important to watch.
Today’s $9.00 52-week high and $8.99 close mark a clear technical milestone for Nutriband. At the same time, the company is approaching the end of a significant warrant window that could potentially provide additional capital while it continues developing AVERSA™.
The next chapter will ultimately depend on execution — including regulatory progress, financing, commercialization, intellectual-property development and the company’s ability to advance its pipeline.
But with NTRB now trading at a new 52-week high, AVERSA™ continuing forward, and the NTRBW warrant deadline arriving September 30, Nutriband has certainly entered a period that warrants close attention as September comes to an end.
For more information on NTRB visit: https://www.nutriband.com
Nutriband, Inc.
121 South Orange Avenue
Suite 1500
Orlando, Fl 32801
Phone: 407-377-6695
Email: info@nutriband.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: CorporateAds
Follow the full story here: https://przen.com/pr/33624643
Media gallery
